Login
From:
Pulmonary Fibrosis News
(Uncensored)
subscribe
Potential IPF add-on therapy NXP002 reduces fibrosis markers, early tests show | Nuformix plans to test NXP002 on lung tissue from patients, healthy voluntee...
https://pulmonaryfibrosisnews.com/news/early-lab-tests-ipf-add-on-nxp002-reduces-fibrosis-markers/
links
backlinks
Tagged with:
idiopathic pulmonary fibrosis
nxp002
nuformix
antifibrotic properties
disease model
Treatment with Nuformix's experimental therapy NXP002 reduced markers of fibrosis in a laboratory model of idiopathic pulmonary fibrosis.
Roast topics
Find topics
Find it!
